Subscribe to Journal
Get full journal access for 1 year
only $131.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med. 2012;366:1075–7.
Trogdon JG, Falchook AD, Basak R, Carpenter WR, Chen RC. Total medicare costs associated with diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol. 2019;5:60–6.
Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–90.
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190:429–38.
Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M et al. SEER cancer statistics review, 1975–2016. Bethesda, MD: National Cancer Institute. Bethesda; 2019.
Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 2017;3:705–7.
Zavaski ME, Meyer CP, Sammon JD, Hanske J, Gupta S, Sun M, et al. Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 USPSTF recommendations. JAMA Intern Med. 2016;176:546–7.
Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR et al. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020;23:81–7.
Miller DC, Gust C, Dimick JB, Birkmeyer N, Skinner J, Birkmeyer JD. Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff. 2011;30:2107–15.
Bozic KJ, Ward L, Vail TP, Maze M. Bundled payments in total joint arthroplasty: targeting opportunities for quality improvement and cost reduction. Clin Orthop Relat Res®. 2014;472:188–93.
Q-DT is supported by the Brigham Research Institute Fund to Sustain Research Excellence, the Bruce A. Beal and Robert L. Beal Surgical Fellowship, the Genentech Bio-Oncology Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (grant # 10202), a Health Services Research pilot test grant from the Defense Health Agency, the Clay Hamlin Young Investigator Award from the Prostate Cancer Foundation (grant # 16YOUN20), and an unrestricted educational grant from the Vattikuti Urology Institute.
Conflict of interest
Q-DT reports consulting fees from Bayer, Astellas, and Janssen. All other authors have nothing to disclose.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
McClintock, T.R., Cone, E.B., Marchese, M. et al. Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer Prostatic Dis (2020). https://doi.org/10.1038/s41391-020-0239-x